TP53 and acute lymphoblastic leukemia: Growth inhibition following treatment with the MDM2 inhibitor RG7388, either alone or in combination with BBI608, was evaluated in both p53 wild-type (p53WT) and p53 mutant (p53MUT) ALL cell lines, including Nalm-6, RS4;11, and HAL-01 for p53WT, and MOLT-4, REH, and CCRF-CEM for p53MUT.